Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more
Market Cap & Net Worth: Hemogenyx Pharmaceuticals Plc (HOPHF)
Hemogenyx Pharmaceuticals Plc (PINK:HOPHF) has a market capitalization of $7.97 Million ($7.97 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #31666 globally and #10421 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hemogenyx Pharmaceuticals Plc's stock price $1.24 by its total outstanding shares 6425429 (6.43 Million).
Hemogenyx Pharmaceuticals Plc Market Cap History: 2020 to 2025
Hemogenyx Pharmaceuticals Plc's market capitalization history from 2020 to 2025. Data shows growth from $835.31K to $7.97 Million (68.54% CAGR).
Hemogenyx Pharmaceuticals Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hemogenyx Pharmaceuticals Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HOPHF by Market Capitalization
Companies near Hemogenyx Pharmaceuticals Plc in the global market cap rankings as of March 19, 2026.
Key companies related to Hemogenyx Pharmaceuticals Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Hemogenyx Pharmaceuticals Plc Historical Marketcap From 2020 to 2025
Between 2020 and today, Hemogenyx Pharmaceuticals Plc's market cap moved from $835.31K to $ 7.97 Million, with a yearly change of 68.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $7.97 Million | +39900.00% |
| 2024 | $19.92K | -92.25% |
| 2023 | $257.02K | +183.69% |
| 2022 | $90.60K | -51.88% |
| 2021 | $188.27K | -77.46% |
| 2020 | $835.31K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Hemogenyx Pharmaceuticals Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.97 Million USD |
| MoneyControl | $7.97 Million USD |
| MarketWatch | $7.97 Million USD |
| marketcap.company | $7.97 Million USD |
| Reuters | $7.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.